Inhibikase Therapeutics (NYSE:IKT – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Institutional and Insider Ownership
3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 20.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 16.7% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Inhibikase Therapeutics and Kymera Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibikase Therapeutics | $260,000.00 | 39.13 | -$19.03 million | ($3.56) | -0.44 |
| Kymera Therapeutics | $78.59 million | 28.31 | -$146.96 million | ($2.52) | -14.45 |
Profitability
This table compares Inhibikase Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibikase Therapeutics | -5,886.15% | -107.54% | -91.82% |
| Kymera Therapeutics | -187.00% | -34.83% | -25.30% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Inhibikase Therapeutics and Kymera Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibikase Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Kymera Therapeutics | 0 | 6 | 7 | 0 | 2.54 |
Inhibikase Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 1,608.86%. Kymera Therapeutics has a consensus price target of $41.20, indicating a potential upside of 12.69%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than Kymera Therapeutics.
Risk and Volatility
Inhibikase Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
